Abstract
Background: Granulomatosis with polyangiitis (GPA) which also known as Wegener's Granulomatosis is a rare disease. GPA is a heterogeneous disease that involves different organs with variable severities and a relapsing course.
Objective: This study aimed to investigate the demographic data, clinical and laboratory presentations, prevalence of involvement in various organs, therapeutic regimens, response to treatment and relapse rate in Granulomatosis with polyangiitis (GPA) patients in Yazd Province, central Iran.
Method: This is a retrospective descriptive study, including 27 patients with definite diagnosis of GPA from 2005 to 2014. Mean duration of follow up was 5 years.
Results: Patients mean age was 35.42 years and male/female ratio 1.45. Initially involved organs were lower respiratory tract (40.7%), musculoskeletal system (33.3%) and upper respiratory tract (25.9%). In course of disease upper respiratory tract (74.7%), renal system (66.7%) and lower respiratory tract (62.9%) were the most involved organs. Cytoplasmic anti-neutrophilic cytoplasmic antibodies (cANCA) was positive in 88.8% and perinuclear anti-neutrophilic cytoplasmic antibodies (pANCA) in 18.51% of patients. Erythrocyte sedimentation rate (ESR) was high in 88.8%. Therapeutic regimens included prednisolone and cyclophosphamide were prescribed for induction in most patients (88.8%). Three patients were treated with plasmapheresis due to diffuse alveolar hemorrhage (DAH), and three with Rituximab due to refractory to conventional treatment, successfully. Complete remission was seen in 44.4% and partial remission in 33.3% patients after three months, also in 74.07% and 14.81% of cases after 12 months. Relapse occurred in 66.7% of cases. There was no significant correlation between cANCA and clinical manifestation or outcome in this study. (P value>0.05).
Conclusion: In our patients, the involvement of lower respiratory tract was more than the upper part as presentation. However, during the course of disease involvement of the upper respiratory tract was observed more. Administration of rituximab was successful in patients with refractory to conventional therapy.
Keywords: Anti-neutrophil cytoplasmic antibodies, diffuse alveolar hemorrhage, follow-up, granulomatosis with polyangiitis (GPA), respiratory tract involvement, vasculitis.
Current Respiratory Medicine Reviews
Title:Outcome of 27 Patients with Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Patients in Iran
Volume: 14 Issue: 3
Author(s): Hossein Soleymani Salehabadi, Amir Behnam Kharazmi*, Shady Mostafavy, Sanaz Zand and Ali Dehghan
Affiliation:
- Department of Pulmonology, Shahid Beheshti University of Medical Sciences, Tehran,Iran
Keywords: Anti-neutrophil cytoplasmic antibodies, diffuse alveolar hemorrhage, follow-up, granulomatosis with polyangiitis (GPA), respiratory tract involvement, vasculitis.
Abstract: Background: Granulomatosis with polyangiitis (GPA) which also known as Wegener's Granulomatosis is a rare disease. GPA is a heterogeneous disease that involves different organs with variable severities and a relapsing course.
Objective: This study aimed to investigate the demographic data, clinical and laboratory presentations, prevalence of involvement in various organs, therapeutic regimens, response to treatment and relapse rate in Granulomatosis with polyangiitis (GPA) patients in Yazd Province, central Iran.
Method: This is a retrospective descriptive study, including 27 patients with definite diagnosis of GPA from 2005 to 2014. Mean duration of follow up was 5 years.
Results: Patients mean age was 35.42 years and male/female ratio 1.45. Initially involved organs were lower respiratory tract (40.7%), musculoskeletal system (33.3%) and upper respiratory tract (25.9%). In course of disease upper respiratory tract (74.7%), renal system (66.7%) and lower respiratory tract (62.9%) were the most involved organs. Cytoplasmic anti-neutrophilic cytoplasmic antibodies (cANCA) was positive in 88.8% and perinuclear anti-neutrophilic cytoplasmic antibodies (pANCA) in 18.51% of patients. Erythrocyte sedimentation rate (ESR) was high in 88.8%. Therapeutic regimens included prednisolone and cyclophosphamide were prescribed for induction in most patients (88.8%). Three patients were treated with plasmapheresis due to diffuse alveolar hemorrhage (DAH), and three with Rituximab due to refractory to conventional treatment, successfully. Complete remission was seen in 44.4% and partial remission in 33.3% patients after three months, also in 74.07% and 14.81% of cases after 12 months. Relapse occurred in 66.7% of cases. There was no significant correlation between cANCA and clinical manifestation or outcome in this study. (P value>0.05).
Conclusion: In our patients, the involvement of lower respiratory tract was more than the upper part as presentation. However, during the course of disease involvement of the upper respiratory tract was observed more. Administration of rituximab was successful in patients with refractory to conventional therapy.
Export Options
About this article
Cite this article as:
Salehabadi Soleymani Hossein , Kharazmi Behnam Amir *, Mostafavy Shady , Zand Sanaz and Dehghan Ali , Outcome of 27 Patients with Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Patients in Iran, Current Respiratory Medicine Reviews 2018; 14 (3) . https://dx.doi.org/10.2174/1573398X14666181019120828
DOI https://dx.doi.org/10.2174/1573398X14666181019120828 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Novel Approaches to the Therapy of Rheumatoid Arthritis based on an Understanding of Disease Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Current Respiratory Medicine Reviews Autoimmune Neuromuscular Disorders
Current Neuropharmacology Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Leptin and Vascular Smooth Muscle
Current Vascular Pharmacology Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction
Current Neuropharmacology The Therapeutic Applications of Exosomes in Different Types of Diseases: A Review
Current Molecular Medicine RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage
Current Neurovascular Research The Role of Cytokines in T Help Responses to Viruses
Current Immunology Reviews (Discontinued) The Potential of Nano-Vehicle Mediated Therapy in Vasculitis and Multiple Sclerosis
Current Pharmaceutical Design